Recently, the China Biotechnology Development Center released the "Guidelines for Clinical Research of New Technologies in Tissue Stem Cell Therapy (Version 1)", which will come into effect on May 1, 2026.

In May 2026, the Drug Evaluation Center of the National Medical Products Administration (CDE) officially released the "2025 Annual Drug Evaluation Report".

On May 13th, the Central Social Insurance and Medical Agreement Committee of the Ministry of Health, Labour and Welfare of Japan officially approved the inclusion of two iPS cell drugs in the national medical insurance coverage.

Recently, the National Health Commission of China has issued the "Standards for the Preparation and Cryopreservation of Umbilical Cord Blood Hematopoietic Stem Cells", which will come into effect on September 1, 2026.

Recently, the US Food and Drug Administration (FDA) released "Framework for Reasonable Mechanisms for the Development of Individualized Therapies for Specific Genetic Diseases with Known Causes" (draft 2026).

In March 2026, there was a vigorous trend in the submission of clinical trials in the field of cell and gene therapy (CGT).

The human-induced pluripotent stem cell (iPSC)-derived dopaminergic neural precursor cell therapy "NCR201" is currently undergoing clinical research at Zhongshan Hospital affiliated to Fudan University.

With the acceleration of global population aging, Parkinson's disease has become the second most common neurodegenerative disorder after Alzheimer's disease, affecting the health and quality of life of over ten million people worldwide.